Filtering

Page: () 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ... 233 ()
OP17 Protein intakes and risk of inflammatory bowel disease in the European Prospective Investigation into Cancer and Nutrition cohort (EPIC-IBD)

ECCO'20 Vienna

Year: 2020
Authors:

C. Dong1, Y. Mahamat-Saleh2, A. Racine3, P. Jantchou4, S. Chan6, A. Hart5, F. Carbonnel3, M.C. Boutron-Ruault2

1Gastroenterology Department, Kremlin Bicetre Hospital, AP-HP, University Paris Sud, Saint-Mandé, France, 2Gustave Roussy Institute, Inserm, Villejuif, France, 3Gastroenterology Department, Kremlin Bicetre Hospital, AP-HP, University Paris Sud, Paris, France, 4Pediatric Department, University of Montreal, Montreal, Canada, 5Gastroenterology Department, Norwich Medical School, Norwich, UK, 6Gastroenterology and Gut Biology Department, Norwich Medical School, Norwich, UK

OP18 Surgical prevention of anastomotic recurrence by excluding mesentery in Crohn’s disease: The SuPREMe-CD study

ECCO'20 Vienna

Year: 2020
Authors:

G. Luglio, A. Rispo, N. Imperatore, A. Amendola, F.P. Tropeano, R. Peltrini, F. Castiglione, G.D. De Palma, L. Bucci

Department of Clinical Medicine, Gastroenterology and Surgery, Federico II University of Naples, Naples, Italy

OP19 Perinatal factors do not affect paediatric inflammatory bowel disease risk: A Scottish Nationwide Cohort study using administrative health data 1981–2017

ECCO'20 Vienna

Year: 2020
Authors:

C. Burgess1,2, C. Schnier3, I. Chalmers4, R.K. Russell5, R. Hansen5, P. Henderson1,2, R. Wood6,7, D.C. Wilson1,2

1Department of Child Life and Health, University of Edinburgh, Edinburgh, UK, 2Department of Paediatric Gastroenterology and Nutrition, Royal Hospital for Sick Children, Edinburgh, UK, 3Centre for Medical Informatics, Usher Institue, Edinburgh, UK, 4Department of Paediatric Gastroenterology and Nutrition, Royal Aberdeen Children’s Hospital, Aberdeen, UK, 5Department of Paediatric Gastroenterology and Nutrition, Royal Hospital for Children, Glasgow, UK, 6Information Services Division, NHS National Services Scotland, Edinburgh, UK, 7Salvesen Mindroom Research Centre, University of Edinburgh, Edinburgh, UK

OP20 The gut microbiota during biological therapy for inflammatory bowel disease

ECCO'20 Vienna

Year: 2020
Authors:

C. Caenepeel1, S. Viera-Silva2, B. Verstockt3, K. Machiels3, N.A. Davani3, J. Sabino3,4, M. Ferrante3,4, J. Raes2, S. Vermeire3,4

1Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Kessel-Lo, Belgium, 2Department of Microbiology and Immunology, Rega Institute for Medical Research, Leuven, Belgium, 3Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium, 4Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium

OP21 Positivity thresholds of total infliximab and adalimumab anti-drug antibody assay: The prevalence of clearing and transient anti-drug antibodies in a national therapeutic drug monitoring service

ECCO'20 Vienna

Year: 2020
Authors:

R. Nice1, N. Chanchlani2, H. Green2, C. Bewshea2, N. Kennedy2, T. Ahmad2, J. Goodhand2, T. McDonald1, M. Perry1

1Department of Blood Sciences, Royal Devon and Exeter Hospital, NHS Foundation Trust, Exeter, UK, 2Exeter IBD Pharmacogenetics, University of Exeter., Exeter, UK

OP22 Crohn’s disease exclusion diet reduces bacterial dysbiosis towards healthy controls in paediatric Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

J. Van Limbergen1, K. Dunn2, E. Wine3, R. Sigall Boneh4, J. Bielawski2, A. Levine4

1Division of Pediatric Gastroenterology and Nutrition, Amsterdam UMC - Location AMC, Amsterdam, The Netherlands, 2Department of Biology, Dalhousie University, Halifax, Canada, 3Department of Paediatric Gastroenterology and Nutrition, University of Alberta, Edmonton, Canada, 4Wolfson Medical Centre, Paediatric Gastroenterology & Nutrition, Holon, Israel

OP23 Efficacy and safety of vedolizumab SC in patients with moderately to severely active Crohn’s disease: Results of the VISIBLE 2 study

ECCO'20 Vienna

Year: 2020
Authors:

S. Vermeire1, W. Sandborn2, F. Baert3, S. Danese4, T. Kobayashi5, E.V. Loftus Jr6, S. Bhatia7, K. Kisfalvi8, M. Rosario9, W. Zhang10, G. D’Haens11

1Department of Gastroenterology, Leuven, Belgium, 2Division of Gastroenterology, La Jolla, University of California - San Diego, USA, 3Department of Gastroenterology, AZ Delta, Roeselare, Belgium, 4Gastrointestinal Immunopathology, Humanitas University, Milan, Italy, 5Center for Advanced IBD Research and Treatment, Kitasato University, Tokyo, Japan, 6Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, USA, 7Takeda, Medical Safety, London, UK, 8Takeda, Research and Development- Global Clinical Sciences, Cambridge, USA, 9Takeda, Clinical Pharmacology, Cambridge, USA, 10Takeda, Statistical and Quantitative Sciences, R&D, Cambridge, USA, 11Department of Gastroenterology, Amsterdam University Medical Centers, Amsterdam, The Netherlands

OP24 A novel subcutaneous infliximab (CT-P13): 1-year results including switching results from intravenous infliximab (CT-P13) in patients with active Crohn’s disease and ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

S. Ben-Horin1, J. Leszczyszyn2, R. Dudkowiak2, A. Lahat3, B. Gawdis-Wojnarska4, A. Pukitis5, M. Horynski6, K. Farkas7, J. Kierkus8, M. Kowalski9, B.D. Ye10, W. Reinisch11, S.J. Lee12, S.H. Kim13, M.R. Kim13, Y.A. Kim13, H.N. Kim14, S. Schreiber15

1Department of Gastroenterology, Sheba Medical Center, University of Tel Aviv, Tel-Hashosmer, Israel, 2Department of Gastroenterology, Melita Medical, Wroclaw, Poland, 3Department of Gastroenterology, Tel Aviv University, Chaim Sheba Medical Center and Sackler School of Medicine, Ramat Gan, Israel, 4Department of Gastroenterology, Twoja Przychodnia, Szczecińskie Centrum Medyczne, Szczecin, Poland, 5Department of Gastroenterology, Center of Gastroenterology, Hepatology, and Nutrition, Pauls Stradins Clinical University Hospital, Riga, Latvia, 6Department of Gastroenterology, Endoskopia Sp. z o.o., Sopot, Poland, 7Department of Clinical Pharmacology, Szent Imre Egyetemi Oktatókórház, Budapest, Hungary, 8Klinika Gastroenterologii, Hepatologii, Zaburzeń Odżywiania i Pediatri, Pomnik Centrum Zdrowia Dziecka, Warsaw, Poland, 9Department of Gastroenterology, Centrum Diagnostyczno, Wloclawek, Poland, 10College of Medicine, Asan Medical Center, Gastroenterology and Inflammatory Bowel Disease Center, University of Ulsan, Seoul, Korea Republic of, 11Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria, 12Division of Clinical Development, CELLTRION Inc., Incheon, Korea Republic of, 13Department of Clinical Planning, CELLTRION Inc., Incheon, Korea Republic of, 14Department of Clinical Statistics, CELLTRION Inc., Incheon, Korea Republic of, 15Department of Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany

OP25 Biologics before surgery for IBD: Are they associated with post-operative infectious outcomes? Results from the national surgical quality improvement programme inflammatory bowel disease collaborative

ECCO'20 Vienna

Year: 2020
Authors:

S. Holubar1, X. Jai1, T. Hull1, N. Hyman2, S. Ramamoorthy3, S. Einsenstein3, National Surgical Quality Improvement Program Inflammatory Bowel Disease Collaborative

1Department of Colon and Rectal Surgery, Cleveland Clinic, Cleveland, USA, 2Department of Surgery, University of Chicago, Chicago, USA, 3Department of Surgery, University of California - San Diego, San Diego, USA

OP26 The first real-life multicentre prospective validation study of the electronic chromoendoscopy score (Paddington International Virtual ChromoendoScopy ScOre) and its outcome in ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

M. Iacucci1, S.C. Smith2, A. Bazarova2, U.N. Shivaji1, P. Bhandari3, R. Cannatelli2, M. Daperno4, J.G. Ferraz5, M. Goetz6, X. Gui7, B. Hayee8, G. De Hertogh9, M. Lazarev10, J. Li11, O.M. Nardone2, V. Occhipinti12, R. Panaccione5, A. Parra-Blanco13, L. Pastorelli12, T. Rath14, G. Tontini15, M. Vieth16, V. Villanacci17, D. Zardo18, R. Kiesslich19, R. Bisschops20, S. Ghosh1

1Department of Gastroenterology, NIHR Birmingham Biomedical Research Centre, Birmingham, UK, 2Department of Gastroenterology, Institute of Translational Medicine, University of Birmingham, Birmingham, UK, 3Department of Gastroenterology, Queen Alexandra Hospital, Portsmouth, UK, 4Department of Gastroenterology, University of Torino, Torino, Italy, 5Department of Gastroenterology, University of Calgary, Calgary, Canada, 6Department of Gastroenterology, Klinikum Boblingen, Boblingen, Germany, 7Department of Pathology, University of Washington, Seattle, USA, 8Department of Gastroenterology, Kings College London, London, UK, 9Department of Pathology, University Hospitals Leuven, Leuven, Belgium, 10Department of Gastroenterology, Johns Hopkins University, Baltimore, USA, 11Department of Gastroenterology, Peking Union Medical College Hospital, Beijing, China, 12Department of Gastroenterology, IRCCS Policlinico San Donato, Milan, Italy, 13Department of Gastroenterology, University of Nottingham, Nottingham, UK, 14Department of Gastroenterology, University of Erlangen, Erlangen, Germany, 15Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, 16Department of Pathology, Kinikum Bayreuth, Bayreuth, Germany, 17Department of Pathology, Institute of Pathology Spedali Civili Brescia, Brescia, Italy, 18Department of Pathology, University Hospital Birmingham NHS Trust, Birmingham, UK, 19Department of Gastroenterology, Helios HSK Wiesbaden, Wiesbaden, Germany, 20Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium

OP27 Long-term safety and efficacy of risankizumab treatment in patients with Crohn’s disease: Final results from the Phase 2 open-label extension study

ECCO'20 Vienna

Year: 2020
Authors:

M. Ferrante1, B.G. Feagan2, J. Panés3, F. Baert4, E. Louis5, O. Dewit6, A. Kaser7, W.R. Duan8, D. Gustafson9, X. Liao10, K. Wallace9, J. Kalabic11, G.R. D’Haens12

1Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium, 2Clinical Trials Design and Management, University of Western Ontario, London, Canada, 3Department of Inflammatory Disease, Hospital Clinic Barcelona, Barcelona, Spain, 4Department of Gastroenterology, AZ Delta, Roeselare-Menen, Belgium, 5Department of Gastroenterology, University of Liège and CHU, Liège, Belgium, 6Department of Gastroenterology, Cliniques Universitaires Saint-Luc, Brussels, Belgium, 7Department of Gastroenterology, University of Cambridge, Cambridge, UK, 8Department of Pharmacovigilance and Patient Safety, AbbVie Inc., North Chicago, USA, 9Department of Immunology, AbbVie Inc., North Chicago, USA, 10Department of Data and Statistical Sciences, AbbVie Inc., North Chicago, USA, 11Department of Immunology, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, 12Department of Gastroenterology, Amsterdam University Medical Center, Amsterdam, The Netherlands

OP28 Gene expression (GE) values in a phase 2 trial of mirikizumab in ulcerative colitis (UC) correlate better with histopathology (HP) than endoscopy (EN) and Mayo scores

ECCO'20 Vienna

Year: 2020
Authors:

B. Steere1, K. GOTTLIEB1, J. Schmitz2, R. Higgs1, B. Jia1, C. Milch1, J. Tuttle3, V. Krishnan1, R. Belin1, W. Reinisch4

1Department of Immunology, Eli Lilly and Company, Indianapolis, USA, 2Department of Discovery Sciences, Eli Lilly and Company, Indianapolis, USA, 3Department of Discovery Sciences, Eli Lilly and Company, San Diego, USA, 4Department of Gastroenterology, Medical University Vienna, Vienna, Austria

OP29 Tofacitinib in ulcerative colitis: Real-world evidence from Eneida Registry

ECCO'20 Vienna

Year: 2020
Authors:

M. Chaparro1, A. Garre1, F. Mesonero2, C. Rodríguez3, M. Barreiro-de Acosta4, J. Martínez-Cadilla5, M.T. Arroyo6, N. Manceñido7, M. Sierra-Ausín8, I. Vera-Mendoza9, M.J. Casanova1, P. Nos10, C. González-Muñoza11, T. Martínez12, M. Boscá-Watts13, D. Busquets14, M. Calafat15, E. Girona16, J. Llaó17, M.D. Martín-Arranz18, M. Piqueras19, L. Ramos20, G. Suis21, F. Bermejo22, A.Y. Carbajo23, D. Casas-Deza24, A. Fernández-Clotet25, M.J. García26, D. Ginard27, A. Gutiérrez-Casbas28, L. Hernández-Villalba29, A.J. Lucendo30, L. Márquez31, O. Merino-Ochoa32, F.J. Rancel33, C. Taxonera34, A. López Sanromán2, S. Rubio3, E. Domènech15, J.P. Gisbert1

1Gastroenterology Unit, Hospital Universitario de La Princesa- IIS-IP- Universidad Autónoma de Madrid- and CIBEREHD, Madrid, Spain, 2Gastroenterology Unit, Hospital Universitario Ramón y Cajal, Madrid, Spain, 3Gastroenterology Unit, Complejo Hospitalario de Navarra, Pamplona, Spain, 4Gastroenterology Unit, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, 5Gastroenterology Unit, Hospital Álvaro Cunqueiro- Complexo Hospitalario Universitario de Vigo, Vigo, Spain, 6Gastroenterology Unit, Hospital Clínico Universitario Lozano Blesa- IIS Aragón and CIBEREHD, Zaragoza, Spain, 7Gastroenterology Unit, San Sebastián de los Reyes, Hospital Universitario Infanta Sofía., Spain, 8Gastroenterology Unit, Complejo Asistencial Universitario de León, León, Spain, 9Gastroenterology Unit, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, 10Department of Gastroenterology Unit, Hospital Universitario y Politécnico La Fe and CIBEREHD, Valencia, Spain, 11Department of Gastroenterology Unit, Hospital Universitario Santa Creu i Sant Pau, Barcelona, Spain, 12Gastroenterology Unit, Hospital Virgen de la Luz, Cuenca, Spain, 13Gastroenterology Unit, Hospital Clinico de Valencia and Universitat de Valencia, Valencia, Spain, 14Gastroenteroloy Unit, Hospital Universitario de Gerona Dr Josep Trueta, Gerona, Spain, 15Gastroenterology Unit, Hospital Germans Trials i Pujol and CIBERehd, Barcelona, Spain, 16Gastroenterology Unit, Hospital General Universitario de Elche, Elche, Spain, 17Gastroenterology Unit, Hospital Sant Joan de Déu- Althaia- Xarxa Assistencial Universitària de Manresa, Barcelona, Spain, 18Gastroenterology Unit, Hospital Universitario La Paz and IdiPaz, Madrid, Spain, 19Gastroenterology Unit, Consorci Sanitari de Terrasa, Barcelona, Spain, 20Gastroenterology Unit, Hospital Universitario de Canarias, Islas Canarias, Spain, 21Gastroenterology Unit, Hospital de Bellvitge and IDIBELL, Barcelona, Spain, 22Gastroenterology Unit, Hospital Universitario de Fuenlabrada. Instituto de Investigación de La Paz IdiPaz, Madrid, Spain, 23Gastroenterology Unit, Hospital Universitario Río Hortega, Valladolid, Spain, 24Gastroenterology Unit, Hospital Universitario Miguel Servet, Zaragoza, Spain, 25Gastroenterology Unit, Hospital Clìnic de Barcelona, Barcelona, Spain, 26Gastroenterology Unit, Hospital Universitario Marqués de Valdecilla and IDIVAL, Santander, Spain, 27Gastroenterology Unit, Hospital Universitario Son Espases, Palma de Mallorca, Spain, 28Gastroenterology Unit, Hospital General Universitario de Alicante and CIBERehd, Alicante, Spain, 29Gastroenterology Unit, Hospital Santos Reyes de Aranda del Duero, Burgos, Spain, 30Gastroenterology Unit, Hospital General de Tomelloso and CIBEREHD, Ciudad Real, Spain, 31Gastroenterology Unit, Hospital del Mar and Institut Hospital del Mar d’Investigacions Mèdiques, Barcelona, Spain, 32Gastroenterology Unit, Hospital Universitario de Cruces, Vizcaya, Spain, 33Gastroenterology Unit, Complejo Hospitalario de Palencia, Palencia, Spain, 34Gastroenterology Unit, Hospital Clínico San Carlos and IdISSC, Madrid, Spain

OP30 The interplay of microbiome dysbiosis and immune system deregulation in patients with Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

N.S. Seyed Tabib1, C. Caenepeel1, K. Machiels1, S. Verstockt1, B. Verstockt1,2, N. Ardeshir Davani1, J. Sabino1,2, M. Ferrante1,2, S. Vermeire1,2

1Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium, 2Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium

OP31 Meta–omics reveals microbiome-driven proteolysis as a contributing factor to the severity of ulcerative colitis disease activity

ECCO'20 Vienna

Year: 2020
Authors:

R. Mills1, P. Dulai2, Y. Vázquez-Baeza3, Q. Zhu3, G. Humphrey3, L. DeRight Goldasich3, R. Quinn4, A. Gewirtz5, B. Chassaing5, H. Chu6, W. Sandborn2, P. Dorrestein1, R. Knight3, D. Gonzalez1

1Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California - San Diego, San Diego, USA, 2Department of Gastroenterology, University of California - San Diego, San Diego, USA, 3Computer Science and Engineering, University of California - San Diego, San Diego, USA, 4Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, USA, 5Center for Inflammation, Immunity and Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, USA, 6University of California San Diego, Pathology, San Diego, USA

OP32 Mincle signalling promotes intestinal mucosal inflammation through induction of macrophage pyroptosis and neutrophil chemotaxis in Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

W. GONG1, K. Guo2, J. Ren3

1School of Medicine, Southeast University, Nanjing, China, 2Department of General Surgery, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China, 3Department of General Surgery, Jinling Hospital, Nanjing, China

OP33 Multi-omics analysis reveals specific bio-geographical and functional characteristics in inflammatory bowel disease intestinal mucosa

ECCO'20 Vienna

Year: 2020
Authors:

N. Maimon1,2, S. Gerassy-Vainberg1,2, H. Bar-Yosef1, A. Alpert2, E. Starosvetsky2, M. Abu-Arisha1, T. Shvedov1, S. Shen-Orr2, Y. Chowers1, Yehuda Chowers lab Shai Shen-Orr lab Israel

1Department of Gastroenterology, Rambam Health Care Campus, Haifa, Israel, 2Ruth and Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa, Israel

OP34 Whole blood profiling of T-cell-derived miRNA allows the development of prognostic models in inflammatory bowel disease

ECCO'20 Vienna

Year: 2020
Authors:

R. Kalla1, A. Adams2, R. White3, C. Clarke4, A. Ivens3, N. Ventham5, N. Kennedy6, S. McTaggart7, I. IBD Character Consortium8, G.T. Ho1, A. Buck3, J. Satsangi2, IBD Character Consortium

1Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK, 2Nuffield Department of Medicine, University of Oxford, Oxford, UK, 3School of Biological Sciences, University of Edinburgh, Edinburgh, UK, 4LifeArc, Edinburgh BioQuarter, Edinburgh, UK, 5Centre for Genomics Medicine, University of Edinburgh, Edinburgh, UK, 6Department of Gastroenterology, University of Exeter, Exeter, UK, 7Norwich Research Centre, Earlham Institute, Norwich, UK, 8European Commission, Research and Innovation, Brussels, Belgium

OP35 Treatment outcomes of inflammatory bowel disease in the biological era—a nationwide retrospective cohort study in three Nordic countries: Results from the TRINordic study

ECCO'20 Vienna

Year: 2020
Authors:

M. Zhao1, M. Lördal2, E. Langholz3, T. Knudsen4, M. Voutilainen5, M.L. Høivik6, B. Moum6, B. Saebo7, P. Haiko8, C. Malmgren9, M. Coskun10, H.O. Melberg11, J. Burisch12

1Gastrointestinal Unit, Hvidovre Hospital- Copenhagen University, Hvidovre, Denmark, 2Department of Gastroenterology and Hepatology, Danderyds Hospital, Stockholm, Sweden, 3Department of Medical Gastroenterology, Herlev Hospital, Herlev, Denmark, 4Department of Medicine,- Hospital South West Denmark; Department of Regional Health Research- University of Southern Denmark, Odense, Denmark, 5Department of Gastroenterology, University of Turku, Turku, Finland, 6Department of Gastroenterology, Oslo University Hospital, Oslo, Norway, 7Takeda AS, Medical Affairs, Asker, Norway, 8Takeda Oy, Medical Affairs, Helsinki, Finland, 9Takeda Pharma AB, Medical Affairs, Stockholm, Sweden, 10Takeda A/S, Medical Affairs, Taastrup, Denmark, 11Department of Health Management and Health Economics, Institute of Health and Society, University of Oslo, Oslo, Norway, 12Gastrounit- Medical Division, Hvidovre University Hospital, Hvidovre, Denmark

OP36 Investigating the role of bioactives produced by gut bacteria to modulate immune response in inflammatory bowel disease

ECCO'20 Vienna

Year: 2020
Authors:

R. Giri1,2, K. Shamsunnahar3, A. Salim3, R. Capon3, M. Morrison4, P. O Cuiv4, J. Begun1,2

1Faculty of Medicine, The University of Queensland, Brisbane, Australia, 2Mater Research Institute, The University of Queensland, Brisbane, Australia, 3The Institute for Molecular Biosciences, The University of Queensland, Brisbane, Australia, 4The University of Queensland Diamantina Institute, The University of Queensland, Brisbane, Australia

Page: () 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ... 233 ()